(APTO) Company Bio. Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet  Aptose Biosciences stock price history + stock price today + stock chart + seasonality chart + earnings + dividends + century-to-date Dogs of the Dow beating the  UP AFTER EARNINGS: Turtle Beach (HEAR) up 12.3% Cloudera (CLDR) up 11.7% Aptos Biosciences (APTO) up 5.2%. ALSO HIGHER: DXC Technology 

APTO: Aptose Biosciences, Inc. Detailed Estimate. Get the latest Detailed View All Zacks #1 Ranked Stocks. Trades from $1 See Earnings Report Transcript  Get the latest Aptose Biosciences, Inc. APTO detailed stock quotes, stock data, Real-Time ECN, View All Zacks #1 Ranked Stocks Exp Earnings Date, 5/5/ 20. Aptose Biosciences Inc (NASDAQ:APTO) The current consensus among 7 polled investment analysts is to Buy stock in Earnings and Sales Forecasts  APTO | Complete Aptose Biosciences Inc. stock news by MarketWatch. Inc. ( APTO) CEO William Rice on Q4 2019 Results - Earnings Call Transcript. Aptose   18 Mar 2020 Aptose Biosciences Inc. (APTO) shares are taking a pay cut of -44.88% from In the previous quarter, the stock rose 25.46 percent at some point. EPS growth is a percentage change in standardized earnings per share over  (APTO) Company Bio. Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet  Aptose Biosciences stock price history + stock price today + stock chart + seasonality chart + earnings + dividends + century-to-date Dogs of the Dow beating the 

10 Mar 2020 APTO-253 Phase 1b Clinical Study –- Throughout the year, Aptose due to higher net finance income, which increased by $341 thousand compared Stock -based compensation decreased for the year ended December 31, 

Aptose Biosciences Inc (NASDAQ:APTO) The current consensus among 7 polled investment analysts is to Buy stock in Earnings and Sales Forecasts  APTO | Complete Aptose Biosciences Inc. stock news by MarketWatch. Inc. ( APTO) CEO William Rice on Q4 2019 Results - Earnings Call Transcript. Aptose   18 Mar 2020 Aptose Biosciences Inc. (APTO) shares are taking a pay cut of -44.88% from In the previous quarter, the stock rose 25.46 percent at some point. EPS growth is a percentage change in standardized earnings per share over  (APTO) Company Bio. Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet  Aptose Biosciences stock price history + stock price today + stock chart + seasonality chart + earnings + dividends + century-to-date Dogs of the Dow beating the  UP AFTER EARNINGS: Turtle Beach (HEAR) up 12.3% Cloudera (CLDR) up 11.7% Aptos Biosciences (APTO) up 5.2%. ALSO HIGHER: DXC Technology  Current Technical Analysis and interactive chart for $APTO stock / shares. See the current trading Mar 10, Aptose Biosciences, Inc. to Host Earnings Call.

08/06/20, Interim 2020 Earnings Release (Projected). 11/05/20, Q3 11/07/19 | 09:00am, Q3 2019 Earnings Release. Upcoming sector events for APTO THER.

UP AFTER EARNINGS: Turtle Beach (HEAR) up 12.3% Cloudera (CLDR) up 11.7% Aptos Biosciences (APTO) up 5.2%. ALSO HIGHER: DXC Technology  Current Technical Analysis and interactive chart for $APTO stock / shares. See the current trading Mar 10, Aptose Biosciences, Inc. to Host Earnings Call. 10 Mar 2020 APTO-253 Phase 1b Clinical Study –- Throughout the year, Aptose due to higher net finance income, which increased by $341 thousand compared Stock -based compensation decreased for the year ended December 31, 

APTO | Complete Aptose Biosciences Inc. stock news by MarketWatch. Inc. ( APTO) CEO William Rice on Q4 2019 Results - Earnings Call Transcript. Aptose  

(NASDAQ:APTO) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 10, 2020 at GlobeNewswire•last  APTO: Aptose Biosciences, Inc. Detailed Estimate. Get the latest Detailed View All Zacks #1 Ranked Stocks. Trades from $1 See Earnings Report Transcript  Get the latest Aptose Biosciences, Inc. APTO detailed stock quotes, stock data, Real-Time ECN, View All Zacks #1 Ranked Stocks Exp Earnings Date, 5/5/ 20. Aptose Biosciences Inc (NASDAQ:APTO) The current consensus among 7 polled investment analysts is to Buy stock in Earnings and Sales Forecasts  APTO | Complete Aptose Biosciences Inc. stock news by MarketWatch. Inc. ( APTO) CEO William Rice on Q4 2019 Results - Earnings Call Transcript. Aptose  

Find the latest and the upcoming Aptose Biosciences earnings report Mar 18, The TipRanks Smart Score analyzes stocks based on 8 factors extracted from 

18 Mar 2020 Aptose Biosciences Inc. (APTO) shares are taking a pay cut of -44.88% from In the previous quarter, the stock rose 25.46 percent at some point. EPS growth is a percentage change in standardized earnings per share over  (APTO) Company Bio. Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet  Aptose Biosciences stock price history + stock price today + stock chart + seasonality chart + earnings + dividends + century-to-date Dogs of the Dow beating the  UP AFTER EARNINGS: Turtle Beach (HEAR) up 12.3% Cloudera (CLDR) up 11.7% Aptos Biosciences (APTO) up 5.2%. ALSO HIGHER: DXC Technology  Current Technical Analysis and interactive chart for $APTO stock / shares. See the current trading Mar 10, Aptose Biosciences, Inc. to Host Earnings Call.

23 Mar 2020 The forecasts give the Aptose Biosciences Inc. stock a price target range of Analysts estimate the earnings to increase 26.70% in the current  3 Stocks Driving The Drugs Industry Higher · By TheStreet Wire. Jul 30, 2015 4: 33 PM EDT. We apologize for any inconvenience. Refresh or try again later. 2 Mar 2020 The shares of Aptose Biosciences Inc. (NASDAQ:APTO) has been pegged with 2020, to Buy the APTO stock while also putting a $9 price target. The company in its last quarterly report recorded -$0.12 earnings per share